#Vaccine Market Size

[industryforecastnews]

Vaccine Market To Reach USD 110.54 Billion By 2030

Vaccine Market Growth & Trends

The global vaccine market size is expected to reach USD 110.54 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.74% from 2024 to 2030. The growth is attributed to the rising immunization programmes, and the development of vaccines for diseases, such as RSV and Chlamydia amongst others. There has been significant progress in improving access to vaccines for diseases of public health concern. Many new vaccines have been developed and distributed globally, resulting in the saving of countless lives and the prevention of various illnesses.

Furthermore, there are several initiatives in the vaccine market aimed at improving access to vaccines, developing new vaccines, and ensuring vaccine safety. These initiatives involve international organizations, governments, private sector entities, and philanthropic organizations. Through collaboration and innovation, these initiatives are helping to address global health challenges and improve public health outcomes. For instance, COVAX is a global initiative aimed at ensuring equitable access to COVID vaccines. The initiative is co-led by Gavi, the Vaccine Alliance, the World Health Organization (WHO), and the Coalition for Epidemic Preparedness Innovations (CEPI).

Although there are over 90 vaccine manufacturers supplying vaccines to World Health Organization Member States in 2021, supply remains highly dependent on fewer than 10 manufacturers with diverse deployable technology and global reach. This concentration leads to regional supply insecurity and market health issues, particularly in the African and Eastern Mediterranean regions. It is anticipated that the COVID vaccine market could go private in the second half of 2023 in the U.S. This privatization may lead to an increase in prices of COVID vaccines and open up the market for other players as well. For instance, both Moderna and Pfizer BioNTech have announced that the prices of their respective mRNA COVID vaccines could increase to around USD 110 to USD 130 per shot.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/vaccine-market

Vaccine Market Report Highlights

By type, the mRNA segment dominated the vaccine market with a share of 32.32% in 2023. However, the subunit vaccine segment is expected to grow at the fastest CAGR of 8.1% during the forecast period

By route of administration, the parenteral administration is anticipated to capture the majority of the vaccine market share throughout the forecast period. Parenteral administration reduces the risk of contamination compared to other routes of administration thus contributing to the segments’ dominance

By disease indication, the viral diseases segment captured the largest share of the vaccine market in 2023, majorly attributed to the high distribution of COVID-19 vaccines during 2021 and 2022

By age, pediatrics is expected to witness the fastest growth during the forecast period, as many countries have established national immunization programs that require children to receive certain shots as part of routine childhood vaccinations

By distribution channel, pharmacies are anticipated to be the fastest-growing segment. This growth can be attributed to the increased accessibility and convenience for patients, and the potential for increased revenue and profitability for pharmacies

North America region is expected to grow at the fastest CAGR during the forecast period. The region is dominated by a few key players, including Pfizer, Moderna, Sanofi Pasteur, and Merck. These companies have a strong presence in the market, with established distribution networks and significant investment in vaccine research and development

Vaccine Market Segmentation

Grand View Research has segmented the global vaccine market on the basis of type, route of administration, disease indication, age group, distribution channel, and region

Vaccine Type Scope Outlook (Revenue, USD Billion, 2018 - 2030)

Subunit Vaccines

Recombinant vaccines

Conjugate Vaccines

Toxoid vaccines

Inactivated

Live Attenuated

mRNA vaccines

Viral vector vaccines

Vaccine Route Of Administration Scope Outlook (Revenue, USD Billion, 2018 - 2030)

Oral

Parenteral

Nasal

Vaccine Disease Indication Scope Outlook (Revenue, USD Billion, 2018 - 2030)

Viral Diseases

Hepatitis

Influenza

HPV

MMR

Rotavirus

Herpes Zoster

Covid-19

Others

Bacterial Vaccines

Meningococcal Diseases

Pneumococcal diseases

DPT

Others

Cancer Vaccines

Allergy Vaccines

Vaccine Age Scope Outlook (Revenue, USD Billion, 2018 - 2030)

Pediatric

Adult

Vaccine Distribution Channel Scope Outlook (Revenue, USD Billion, 2018 - 2030)

Hospital & Retail Pharmacies

Government Suppliers

Others

Vaccine Regional Outlook (Revenue, USD Billion, 2018 - 2030)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

China

Japan

India

South Korea

Australia

Thailand

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

List of Key Players in the Vaccine Market

Serum Institute of India Pvt. Ltd.

Seqirus

Sanofi

GSK Plc.

Merck & Co., Inc.

Pfizer Inc.

Moderna Inc.

Sinovac

BioNTech SE

AstraZeneca

Browse Full report: https://www.grandviewresearch.com/industry-analysis/vaccine-market

[bishtmeenakshi]

Vaccinating the World: Can the Market Deliver on Its Promise?

Explore the potential of the vaccine market to deliver on its promise of global immunization. Analyze trends, size, and future outlook across various vaccine segments, including pneumococcal, dengue, DNA, typhoid fever, and foot and mouth disease vaccines market.

[colinwilson11]

Viral Vaccine Cell Culture Media Market Will Grow At Highest Pace Owing To Rising Prevalence Of Viral Infections

Viral vaccine cell culture media are essential growth mediums required for the propagation of viruses, used in the manufacturing of viral vaccines. It provides necessary nutrients to sustaining and propagation of cells outside of living organism. The composition of viral vaccine cell culture media varies depending on specific requirements and types of viruses being cultivated. It contains necessary salts, amino acids, proteins, vitamins and other organic compounds essential for growth of cells. The advantages associated with viral vaccine cell culture media include standardized and defined composition, ease of scale-up for large-scale manufacturing, and supporting growth of anchorage-dependent and suspension-adapted cells. The need for viral vaccine cell culture media is growing owing to rising incidences of viral infections and technological advancements in vaccine development.

The Viral Vaccine Cell Culture Media Market is estimated to be valued at US$ 1.8 Bn in 2024 and is expected to exhibit a CAGR of 5.8 % over the forecast period 2024-2031.

Key Takeaways

Key players operating in the viral vaccine cell culture media are Thermo Fisher Scientific, Merck, Sartorius,Creative Biolabs, Xell. Thermo Fisher Scientific dominates the market with wide range of viral vaccine cell culture media products.

Rising prevalence of viral infections such as influenza, COVID-19, hepatitis, and others is driving the demand for viral vaccines exponentially. As viral vaccines are manufactured using cell culture technologies, their growing demand is directly fueling the viral vaccine cell culture media market.

Advancements in cell culture technologies, serum-free and chemically defined media are helping overcome issues related to undefined compositions and lot-to-lot inconsistencies. These technologies are supporting more reproducible and scalable manufacturing of viral vaccines.

Market Trends

Serum-free and chemically defined media - These media eliminates risks of contamination from animal-derived components and assists consistent performance during vaccine production. Major players are focusing on development of serum-free formulations.

Single-use bioreactors and technologies - Single-use technologies are helping achieve flexible, consistent and scalable production compared to conventional stainless-steel bioreactors. This trend is positively impacting the viral vaccine cell culture media market.

Market Opportunities

Rising viral vaccine production in developing economies due to increasing disease burden is creating opportunities for viral vaccine cell culture media manufacturers to expand in emerging markets. Adoption of continuous manufacturing technologies using perfusion platforms can further improve productivity and efficiency of viral vaccine production. This presents lucrative opportunities for media manufacturers.

Impact Of COVID-19 On Viral Vaccine Cell Culture Media Market Growth

The outbreak of COVID-19 pandemic has severely impacted the growth of viral vaccine cell culture media market globally. The increased demand for vaccine development caused disturbance in the supply chain and manufacturing process of cell culture media. The lockdowns imposed by governments across various countries led to temporary closure of production facilities and disrupted import-export activities. This affected the availability of raw materials and components required for manufacturing cell culture media. Furthermore, restrictions on travel and transportation made it difficult for companies to conduct clinical trials and testing of vaccines under development.

However, with gradual lifting of lockdowns and resumption of business operations, the market is expected to regain lost momentum in post-COVID times. There is surge in R&D funding from governments and private organizations towards development of vaccines against coronavirus. This has boosted the demand for cell culture media from biopharmaceutical companies. Various start-ups and established players have entered into strategic collaborations with research institutes working on COVID-19 vaccines. They are focusing on expanding their production capacities to meet the growing requirements. Moreover, shift towards single-use technologies and automated solutions is expected to enhance production efficiency. Advancements in cell culture protocols will further drive the market growth in coming years.

Geographically, North America holds the major share of viral vaccine cell culture media market in terms of value, led by substantial research funding and presence of leading biopharma companies. Asia Pacific is emerging as the fastest growing regional market, supported by increasing government initiatives, improving healthcare infrastructure and growth of biosimilars industry in China and India. Recently, several Chinese manufacturers have started offering antibody and cell-based therapeutics against coronavirus. This is likely to boost the uptake of viral cell culture media in Asia Pacific post pandemic.

Impact Of COVID-19 On Viral Vaccine Cell Culture Media Market Growth In India

The COVID-19 outbreak hit India during the initial months of 2020. The country went into a nationwide lockdown enforcing travel restrictions and closure of non-essential services. This impacted the biopharmaceutical industry and temporarily disrupted the supply of cell culture media. Local production was halted as workforce mobility was constrained. Import of critical raw materials from other countries also reduced due to global supply chain disarray.

As a result, several vaccine developers faced challenges in terms of insufficient stock of cell culture media for ongoing R&D activities. Their pre-clinical research and clinical trials got delayed. However, as the lockdown rules were relaxed phase-wise, the Indian government initiated measures to resume operations following strict safety norms. It provided regulatory clearances and financial incentives for ramping up indigenous manufacturing of vaccine components including cell culture media.

India currently holds around 8-10% share of global biologics production. Post pandemic, efforts are being directed towards building self-reliance in vaccine manufacturing. Local players are augmenting their production capacities of viral cell culture media in collaboration with research institutes. Additionally, foreign companies are also evaluating India as an alternative manufacturing hub due to lower costs and large talent pool availability. Thus, India is anticipated to be one of the fastest growing regional markets for viral vaccine cell culture media in coming years.

Get more insights on this topic:  https://www.trendingwebwire.com/viral-vaccine-cell-culture-media-market-set-to-grow-due-to-advancements-in-cell-culture-techniques/

Author Bio

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups. (LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)

What Are The Key Data Covered In This Viral Vaccine Cell Culture Media Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Viral Vaccine Cell Culture Media Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Viral Vaccine Cell Culture Media Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Viral Vaccine Cell Culture Media Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Viral Vaccine Cell Culture Media Market vendors

FAQ’s

Q.1 What are the main factors influencing the Viral Vaccine Cell Culture Media Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Viral Vaccine Cell Culture Media Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Viral Vaccine Cell Culture Media Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[mitalipingale]

The Tetanus Toxoid Vaccine Market in 2023 is US$ 4.75 billion, and is expected to reach US$ 7.64 billion by 2031 at a CAGR of 6.1%.

[marketsndata]

[nihannx]

Global Varicella Vaccine Market 2024 Key Players, Analysis, Share, Trends And Forecast To 2034

The Varicella Vaccine market report offered by Reports Intellect is meant to serve as a helpful means to evaluate the market together with an exhaustive scrutiny and crystal-clear statistics linked to this market. The report consists of the drivers and restraints of the Varicella Vaccine Market accompanied by their impact on the demand over the forecast period. Additionally, the report includes the study of prospects available in the market on a global level.

With tables and figures helping evaluate the Global Varicella Vaccine market, this research offers key statistics on the state of the industry and is a beneficial source of guidance and direction for companies and entities interested in the market. This report comes along with an additional Excel data-sheet suite taking quantitative data from all numeric forecasts offered in the study.

Get Sample PDF Brochure @ https://www.reportsintellect.com/sample-request/2911434

Key players offered in the market: Merck GSK Shanghai Institute BCHT Changsheng Keygen Green Cross Biken

Additionally, it takes account of the prominent players of the Varicella Vaccine market with insights including market share, product specifications, key strategies, contact details, and company profiles. Similarly, the report involves the market computed CAGR of the market created on previous records regarding the market and existing market trends accompanied by future developments. It also divulges the future impact of enforcing regulations and policies on the expansion of the Varicella Vaccine Market.

Scope and Segmentation of the Varicella Vaccine Market

The estimates for all segments including type and application/end-user have been provided on a regional basis for the forecast period from 2024 to 2034. We have applied a mix of bottom-up and top-down methods for market estimation, analyzing the crucial regional markets, dynamics, and trends for numerous applications. Moreover, the fastest & slowest growing market segments are pointed out in the study to give out significant insights into each core element of the market.

Varicella Vaccine Market Type Coverage: - Injection Freeze-Dried Powder

Varicella Vaccine Market Application Coverage: - Kids Injection Adults Injection

Regional Analysis:

North America Country (United States, Canada) South America Asia Country (China, Japan, India, Korea) Europe Country (Germany, UK, France, Italy) Other Countries (Middle East, Africa, GCC)

Discount PDF Brochure @ https://www.reportsintellect.com/discount-request/2911434

The comprehensive report provides:

Complete assessment of all opportunities and threats in the global market.

Varicella Vaccine Market recent advancements and major events.

A thorough study of business policies for the growth of the Varicella Vaccine Market leading players.

Concluding study about the growth plot of Varicella Vaccine Market for upcoming years.

Detailed understanding of Varicella Vaccine Market particular drivers, restraints, and major micro markets.

Favorable impression inside vital technological and market latest trends hitting the Varicella Vaccine Market.

Reasons to Purchase Varicella Vaccine Market Research Report

Develop a competitive approach based on the competitive landscape

Build business strategy by identifying the high growth and attractive Varicella Vaccine market classifications

Identify potential business partners, gaining targets and business buyers

Design financial investment policies based on estimated high potential segments

Prepare management and tactical presentations using the Varicella Vaccine market data

Plan for new product promotion and portfolio in advance

Contact Us: sales@reportsintellect.com Phone No: + 1-706-996-2486 US Address: 225 Peachtree Street NE, Suite 400, Atlanta, GA 30303

[trendingreportz]

DNA Vaccines Market - Forecast(2024 - 2030)

 DNA Vaccines Market is forecast to reach revenue of $9.43 Billion by 2025, growing at a CAGR of 33.86% during the forecast period 2020-2025. DNA vaccines are composed of deoxyribonucleic acid, which encodes antigens and stimulates a wider range of immune responses in the body with few side effects. DNA based Vaccines concept deliver to cells after which the gene is expressed and can generate the protein of interest. Clinical trials of some DNA vaccines have shown promising results in the treatment of several types of cancers like metastatic melanoma, prostate carcinoma, pancreatic cancer, and other solid tumors. The demand for DNA Vaccines is experiencing rapid growth owing to factors such as adoption of DNA Vaccines in Healthcare, Low cost, Increasing Technology, fewer side effects, increasing awareness about Health professionals and others. With the rise of COVID-19 pandemic throughout the world 

Request Sample

Key Takeaways

North America dominates the DNA Vaccines Market owing to the increasing prevalence of infectious diseases in countries such as U.S and Canada.

Adoption of DNA Vaccines in Healthcare, Low cost, Increasing Technology, fewer side effects, increasing awareness about Health professionals are some of the key factors which are leading the demand for DNA Vaccines.

With the current COVID-19 Outbreak there is a huge demand for vaccination that can hack to build better immunity in order to fight the virus

Detailed analysis of the Strength, Weakness, and opportunities of the prominent players operating in the market will be provided in the DNA Vaccines Market.

By Type – Segment Analysis 

Based on the types, the DNA Vaccines Market is segmented into Human DNA Vaccines and Animal DNA Vaccines. Animal DNA vaccine is dominating the market in 2019 and is estimated to grow at a CAGR of 19.8% during the forecast period 2020-2025. This is owing to the unavailability of human DNA vaccines in the market along with the rising incidence of canine melanoma and other animal diseases. Animal vaccines are third generation vaccines and contain DNA that codes for specific proteins from a pathogen. This DNA is injected into host body and produces protein for which the body generates immune response. Moreover, the strong pipeline of human targeted vaccines is likely to aid in the market growth

Inquiry Before Buying

By Application – Segment Analysis

Based on the applications, DNA Vaccines Market is segmented into Human Diseases which includes applications in Oncology, Infectious Disease, Allergies, and Veterinary Disease. The Veterinary Disease based on application is forecast to grow at a higher CAGR during the forecast period 2020-2025 owing to availability of DNA vaccines for animal diseases that includes canine melanoma vaccine (DOG), West Nile Innovator (Horse), Life tide-SW5 (Swine and other food animals) and Apex-IHN (Salmon fish). 

By Geography – Segment Analysis

Based on the geography the DNA Vaccines Market has covered globally viz North America, South America, Europe, Asia Pacific (APAC) and Rest of World (ROW). The Market in North America accounts for 43.7% of the total market share, which is attributed by government initiatives to immune citizens, coupled with high awareness regarding the benefits of genetic vaccines targeted towards animals. 

Asia Pacific region is set to be the highest growth during the forecast period 2020-2025 owing to rising awareness of people regarding the advantages of immunization against HPV and Hepatitis B. Additionally, it is estimated that the DNA Vaccines Market is set to grow exponentially during the forecast period 2020-2025 owing to COVID-19 outbreak.

Schedule a Call

Market Drivers - DNA Vaccines Market

Rising Demand for effective treatment of infectious disease in driving market

DNA Vaccines used to kill and stop the growth of microorganisms. These drugs can act as a defense system for the human body and neutralize the action of disease causative agents. With increasing research activities and Increasing awareness and extensive R&D drugs, there is rising demand for treatment of infectious diseases

Challenges - DNA Vaccines Market

The main area of uncertainty is related to the immunological impact, tissue distribution and persistence after injection and whether the DNA vaccine can leak into the environment. This, in turn, create a challenging point for the growth of DNA Vaccine. Also, with, the limited efficiency of plasmid-based techniques precluded their use in the creation of more accurate human cell models is one of the challenges for DNA Vaccine Market

Buy Now

Vitamin & Mineral Industry Outlook

Product launches, mergers and acquisitions, joint ventures and R&D activities are key strategies adopted by players in the DNA Vaccines Market. In 2019, DNA Vaccines Market share is consolidated by the top ten players present in the market. DNA Vaccines Market Top 10 companies include Inovio Biomedical Corp, Merck & Co., Mitsubishi Tanabe, Dendreon Corporation, ASTELLAS PHARMA, Dynavax Technologies, Sanofi, Tekmira Pharmaceuticals GlaxoSmithKline Corp, Protein Sciences Corp.among others.

Acquisitions/Product Launches

In February 2020, Merck& Co announced the formation of a new, independent publicly-traded company focused on its Women’s Health, trusted Legacy Brands, and Biosimilars business. 

In February 2019, Merck & Co announced its acquisition of Immune Design Corp for nearly $300 million, gaining access to its immunotherapy programs.

[soumyafwr]

Human Papillomavirus (HPV) Vaccines Market Analysis, Size, Share, and Forecast 2031

[xhealer]

Vaccine adjuvants are substances added to vaccines to enhance the body’s immune response to the provided antigen.

[poonamcmi]

Influenza Vaccines Market Driven by High Prevalence of Influenza Globally

The influenza vaccines market overview comprises influenza vaccines marketed for both seasonal and pandemic influenza. Influenza vaccines effectively provide immunity against various influenza strains by activating the immune system to produce specific antibodies. It helps prevent the flu or makes symptoms milder if contracted.

The influenza vaccines market is estimated to be valued at USD 8.30 Bn in 2024 and is expected to reach USD 13.43 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7.1% from 2024 to 2031.

Key Takeaways Key players operating in the influenza vaccines market are Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, BioHorizons, Inc., Harbor MedTech, Inc., MLM Biologics Inc., Geistlich Pharma AG, Olaregen Therapeutix, Inc., EnColl Corporation, Kerecis limited, DSM, ACell Inc., 3M, Cell Constructs I, LLC, CG bio Inc., and Marine Polymer Technologies, Inc. The key opportunities in the influenza vaccines market include new product developments targeting specific age groups and strains, potential pandemic opportunities, increasing government support to promote vaccination programs, and growing healthcare Infrastructure across emerging economies. Globally, manufacturers are focused on expanding their production facilities and distribution networks across Asia Pacific, Latin America, Middle East, and Africa to tap the high growth opportunities in these regions. Market Drivers The high prevalence of influenza globally is the major driver for the Influenza Vaccines Market Demand  As per WHO, influenza causes severe illness in about 3-5 million cases annually. The availability of government funding for vaccination programs especially in developed countries promotes market growth. Furthermore, growing awareness regarding influenza vaccination benefits and initiatives to promote immunization rates support the influenza vaccines market expansion.

PEST Analysis Political: Government Influenza Vaccines Market Size And Trends intervention and international funding on vaccine development through programs and regulations. Focus on preventive healthcare. Economic: Boost in healthcare expenditure. Opportunity for companies to invest in R&D. Vaccine demand expected to rise with awareness. Social: Growing public health concern regarding influenza outbreaks. Higher vaccine uptake due to health consciousness. Technological: Advancements in vaccine production technologies. Continuous innovations to address virus mutations. The United States represents the largest geographical market for influenza vaccines in terms of value, accounting for over 40% share in 2024. Factors such as high healthcare spending, large patient population and rising awareness levels contribute to its leading position. Asia Pacific region is expected to emerge as the fastest growing regional market for influenza vaccines between 2024-2031. Growing middle class population, increasing government support for vaccination programs and expansion of healthcare infrastructure are driving market growth in countries like China and India. Rising cases of influenza outbreaks also emphasize the need for preventive measures through vaccination in the Asia Pacific region.

Get More Insights On, Influenza Vaccines Market

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

[industryforecastnews]

Shingles Vaccine Market Size To Reach USD 11.26 Billion By 2030

Shingles Vaccine Market Growth & Trends

The global shingles vaccine market size is expected to reach USD 11.26 billion by 2030, registering a CAGR of 15.34% during the forecast period, according to a new report by Grand View Research, Inc. Increasing incidence of shingles and high awareness regarding shingles in developed countries are contributing to the market growth. According to the CDC, nearly one million cases of shingles are reported each year in the United States. Furthermore, one out of three individuals in the country will develop the disease in their lifetime.

The increasing adoption of vaccines and an increase in the recommendation of vaccination by different government regulatory bodies are expected to drive the market over the forecast period. For instance, in February 2019, the U.K. Joint Committee of Vaccination and Immunization (JCVI) has recommended the use of the recombinant vaccine to prevent shingles in adults aged 60 to 70 years old.

The inclusion of shingles vaccines in national immunization programs of several countries is anticipated to propel the demand for vaccines. For instance, the shingles vaccine is a part of the national immunization program in the U.K. since 2013. The U.K. is the first country in the European region to introduce shingles vaccine in the national immunization program and it costs around USD 130 to the National Health Service (NHS) for each dose of the vaccine. Similarly, other countries such as the U.S., Italy, Australia, and some provinces of Canada and South Korea have also included the vaccine in their immunization program.

Besides, favorable initiatives undertaken by market players and regulatory bodies to increase the awareness among people who are at risk of developing the disease are expected to fuel the market growth over the coming years. For instance, GlaxoSmithKline plc. has launched a campaign to increase vaccination rates among older adults by educating people about the benefits associated with vaccination.

The high efficacy of vaccines is expected to increase the adoption over the forecast period. According to clinical trial results, Shingrix is highly efficient to prevent shingles and postherpetic neuralgia. Two doses of Shingrix are more than 90% effective to prevent the disease in adults aged 50 years and above. Protection stays above 85% for at least the first four years after getting vaccinated.

The availability of vaccines at lower prices, coupled with a high incidence of the disease and high vaccination rate in developed countries, is anticipated to fuel the market growth. The vaccination rate against shingles in the U.K., the U.S., France, Canada, Germany, and South Korea is higher compared to other countries owing to better reimbursement policies and high awareness levels regarding the disease and vaccines. For instance, the U.K. has the highest shingles vaccine uptake with more than 60% vaccination of eligible adults.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/shingles-vaccine-market-report

Shingles Vaccine Market Report Highlights

By product, Shingrix held the largest share in 2023, owing to the high efficacy of the vaccine as compared to others. Shingrix is also expected to grow at a significant CAGR over the forecast period owing to the increasing recommendations by regulatory bodies to prevent shingles

Based on vaccine type, the recombinant vaccine segment is anticipated to grow at a substantial rate over the forecast period due to the low risk associated with recombinant vaccines

Asia Pacific is projected to witness the fastest growth during the forecast period owing to the high unmet needs and the rising adoption of vaccination programs in the region

North America dominated the market in 2023, due to favorable reimbursement policies and rising initiatives to raise awareness among healthcare professionals and patients.

Shingles Vaccine Market Segmentation

Grand View Research has segmented the global shingles vaccine market based on product, type, end-use, and region:

Shingles Vaccine Product Outlook (Revenue, USD Million, 2018 - 2030)

Shingrix

Zostavax

SKYZoster

Shingles Vaccine Type Outlook (Revenue, USD Million, 2018 - 2030)

Recombinant Vaccine

Live Attenuated Vaccine

Shingles Vaccine End Use Outlook (Revenue, USD Million, 2018 - 2030)

Private Healthcare Settings

Government Healthcare Settings

Shingles Vaccine Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

China

Japan

India

South Korea

Australia

Thailand

Latin America

Brazil

Argentina

Middle East and Africa (MEA)

South Africa

Saudi Arabia

Kuwait

UAE

List of Key Players of Shingles Vaccine Market

GlaxoSmithKline plc.

Merck & Co., Inc.

SK chemicals

Green Cross Corp

Geneone Life Science

Vaccitech

CanSinoBIO

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/shingles-vaccine-market-report

[bishtmeenakshi]

Navigating Innovations in Veterinary Vaccines

Explore the evolving landscape of veterinary vaccines, analyzing market size, segmentation, and revenue. Uncover advancements in areas like the clostridium vaccine and vaccine adjuvants market.

[colinwilson11]

The viral vaccine cell culture media market possesses significant growth opportunities with the increasing prevalence of viral diseases and growing adoption of cell culture-based vaccine production processes. Cell culture media provide nutrients to sustain cell growth and maintain viability outside their natural surroundings. It finds widespread application in the cultivation of cells required for viral vaccine manufacturing.

[mitalipingale]

https://www.pittsburghtribune.org/read-blog/118316_tetanus-toxoid-vaccine-market-share-overview-competitive-analysis-and-forecast-2.html

The Tetanus Toxoid Vaccine Market in 2023 is US$ 4.75 billion, and is expected to reach US$ 7.64 billion by 2031 at a CAGR of 6.1%.

[marketsndata]